Short-Term Safety and Efficacy of Intravitreal Bevacizumab for Pseudophakic Cystoid Macular Edema

Abstract

: Short-term results suggest that intravitreal bevacizumab is safe and well tolerated in patients with pseudophakic cystoid macular edema. Treated eyes had a significant improvement in best corrected visual acuity and decrease in macular thickness by optical coherence tomography.

The management of Irvine-Gass Syndrome in a patient using Inhaler Steroid

“…VEGF is also in lammatory mediators and in lammation is the major etiologic factor in the development of Irvine-Gass syndrome [14,16]. Reported almost immediate improvement of BCVA and complete resolution of CME after a single intravitreal injection of 1.25 mg bevacizumabwhich is a monoclonal antibody against all isoforms of VEGF-A and the improvement was stable for several months without further treatment.…”

“…So, we started topical NSAID treatment at postoperative month 1, in addition to topical steroid which was given for post-cataract treatment. Even still, there are no evidence-based guidelines for the treatment of Irvine-Gass syndrome, several studies have reported signi icant reductions in the macular edema with the topical therapy, after cataract surgery [11][12][13][14]. Combination therapy with topical NSAID and corticosteroidis signi icantly more effective than only corticosteroid in treatment of Irvine-Gass syndrome [15].…”

Prophylaxis of Pseudophakic Cystoid Macular Edema with Intraoperative Pegaptanib

“…7 Recent studies have also shown the usefulness of intravitreal injection of VEGF inhibitors in the treatment of established pseudophakic CME and CME refractory to other treatments. [8][9][10] In view of the success of these agents in the aforementioned indications, we decided to conduct a study to investigate whether one of these inhibitors, pegaptanib, could also be effective in preventing the condition. Our study was designed to evaluate the efficacy of VEGF inhibition by intraoperative injection of pegaptanib, in terms of a reduction in the incidence of CME.…”

“…Pegaptanib has shown some success in the treatment of diabetic ME 17 and refractory pseudophakic CME. 8,9 Several studies have proved the efficacy of bevacizumab for refractory pseudophakic CME, 10,18 and there have been encouraging results when administered preoperatively in patients with diabetic ME (DME) undergoing cataract surgery. [19][20][21] The success of these studies, particularly in relation to patients with DME undergoing cataract surgery, prompted us to investigate whether the prophylactic use of anti-VEGF agents could prevent the onset of pseudophakic CME after uncomplicated procedures.…”

Spectral-Domain Optical Coherence Tomography in Irvine–gass Syndrome

“…As far as the treatment is concerned, it is unknown whether combined assessment of morphology and function, by SD-OCT and visual acuity, can represent effective end points for trials with potential therapeutic drugs, administered either systemically or topically. [10][11][12][13][14] The aim of this observational study was to evaluate longitudinally the macular morphology and function in patients with PCME, treated with oral acetazolamide and topical indomethacin (0.5%), by SD-OCT and Early Treatment Diabetic Retinopathy Study visual acuity. The results indicated that SD-OCT may detect retinal findings, including subtle photoreceptor abnormalities, that are correlated with visual acuity changes in treated PCME eyes.…”